Natalie Sacks
Director/Board Member at CARIBOU BIOSCIENCES, INC.
Net worth: 104 951 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Julia Eastland | F | 59 | 6 years | |
| Rachel Haurwitz | M | 38 | 13 years | |
| Ken Galbraith | M | 61 | 2 years | |
| Martin Roelsgaard Jakobsen | M | - |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 5 years |
| Dara Richardson-Heron | M | 59 | 3 years | |
| Jessica Chao | F | - |
The University of California, San Francisco
| 10 years |
| Jason O’Byrne | M | 54 | 3 years | |
| Nancy Whiting | M | 51 | 3 years | |
| Daniel Dex | M | - | 7 years | |
| Ran Zheng | F | 60 | 3 years | |
| Carlos Campoy | M | 60 | 1 years | |
| David Johnson | M | 55 | 2 years | |
| Patrick Haley | M | 48 | 14 years | |
| Frank Lanza | M | 62 | 5 years | |
| Susan Mahony | M | 60 | 5 years | |
| Derek Miller | M | 54 | 1 years | |
| Robert Williams | M | 75 |
The University of California, San Francisco
| 14 years |
| Claus Elsborg Olesen | M | 50 |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 6 years |
| Scott Braunstein | M | 60 | 3 years | |
| Andrew Guggenhime | M | 55 | 3 years | |
| Barbara McClung | F | 69 | 9 years | |
| Kelvin Neu | M | 50 | 4 years | |
| Troy Cox | M | 60 | 5 years | |
| Steven Kanner | M | 65 | 7 years | |
| Sten Verland | M | 67 |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
| Catherine Graham | F | - | 6 years | |
| Lucas Donigian | M | - | 4 years | |
| Reigin Zawadzki | F | - | 1 years | |
| Diana Papove | F | - | 4 years | |
| Cindy Hayashi | F | - | 8 years | |
| Ryan Fischesser | M | - | - | |
| Elaine Alambra | F | - | - | |
| Richard Bethell | M | 61 |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
| Ramona Doyle | M | 65 |
The University of California, San Francisco
| 13 years |
| Jonathan Leslie Tobin | M | 42 |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 5 years |
| Morten Graugaard Døssing | M | - |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
| Ruhi Khan | F | - | 3 years | |
| Regina Hodits | M | 54 |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
| Kristine Yaffe | M | 61 |
The University of California, San Francisco
| 17 years |
| Paul Moore | M | 58 | 2 years | |
| Danielle Schlosser | M | - |
The University of California, San Francisco
| 11 years |
| Holger Wesche | M | 56 | 6 years | |
| Robin Kate Kelley | M | - |
The University of California, San Francisco
| 15 years |
| Mark Hollywood | M | 55 | 5 years | |
| Timothy Kelly | M | 55 | - | |
| Jeffrey T. L. Smith | M | 64 | 1 years | |
| Christian Schetter | M | 60 |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 5 years |
| David A. Kessler | M | 72 |
The University of California, San Francisco
| 21 years |
| Terence W. Friedlander | M | - |
The University of California, San Francisco
| 13 years |
| Laura O’Connor | F | - | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| N. Coles | M | 63 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 5 years |
| Luke Evnin | M | 60 | 5 years | |
| Georgia Erbez | F | 57 | 4 years | |
| Patrick Baeuerle | M | 66 | 5 years | |
| Gerald McMahon | M | 69 | 5 years | |
| Neil Klompas | M | 52 | 16 years | |
| David J. Scott | M | 71 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | - |
| Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| Ali Tehrani | M | 52 | 9 years | |
| Andrew Robbins | M | 48 | 4 years | |
| Rekha Hemrajani | F | 54 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 10 years |
| Justin Skoble | M | - | 8 years | |
| Joanne Viney | M | 58 | 3 years | |
| Sriram Ryali | M | 43 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 4 years |
| Erik Lium | M | 56 |
The University of California, San Francisco
| 3 years |
| S. Connelly | M | - |
The University of California, San Francisco
| 8 years |
| Craig Dudenhoeffer | M | - |
The University of California, San Francisco
| 16 years |
| Christopher Astle | M | 45 | 2 years | |
| Jeffrey Long-McGie | M | 48 | - | |
| Aimee Luck Murphy | F | - | 9 years | |
| Thomas Wiggans | M | 72 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 8 years |
| Paul Goddard | M | 74 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 16 years |
| Pablo Cagnoni | M | 60 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Alan Colowick | M | 61 | 2 years | |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Helen Torley | M | 61 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| William Ringo | M | 78 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Antonio J. Grillo-López | M | 84 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 11 years |
| Inui Edny | M | - | 3 years | |
| Magnus Åke Lundberg | M | 68 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 13 years |
| Gregory W. Schafer | M | 59 | 5 years | |
| Wendell Wierenga | M | 76 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 17 years |
| Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Joseph Bailes | M | 67 | 4 years | |
| Patrick Rivers | M | - | 2 years | |
| Scott Brown | M | 43 | 2 years | |
| Ted Love | M | 65 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Jeff Knight | M | 53 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 3 years |
| Nicole Keith | F | - |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | - |
| Francesco Galimi | M | 56 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 1 years |
| Mike Ouimette | M | 51 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 1 years |
| Michael Samar | M | 51 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | - |
| Barry Flannelly | M | 66 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 3 years |
| Stefani Wolff | F | 62 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Conrad Jordaan | M | - |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 3 years |
| Flavia Borellini | M | 65 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 1 years |
| Raju Mohan | M | 68 | 5 years | |
| Nisha Nanda | M | 49 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Robert Goeltz | M | 51 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Lucio Tozzi | M | 60 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 92 | 92.00% |
| Denmark | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Natalie Sacks
- Personal Network
